Philip T. Sager, MD
NPI 1427487149ActiveIndividual· Internal Medicine, Cardiovascular Disease· San Francisco, CA
Internal Medicine, Cardiovascular Disease (MD) in San Francisco, California, licensed in CA, with an NPI issued in November 2013. Syndax Pharmaceuticals, Inc. was the largest of 3 companies reporting payments in 2025, $158,025 in all, mostly consulting fees.
Overview
| NPI | 1427487149 |
|---|---|
| Status | Active |
| Entity type | Individual |
| Credential | MD |
| Sole proprietor | Yes |
| NPI issued | Nov 4, 2013 |
| Last updated in NPPES | Nov 4, 2013 |
Specialties and licenses
| Taxonomy | Code | License | State |
|---|---|---|---|
| Internal Medicine, Cardiovascular Disease Primary | 207RC0000X | G62729 | CA |
Exclusion screening
| List | Result | Details |
|---|---|---|
| HHS-OIG LEIE · Nov 10, 2026 | No match | Checked by NPI and by name + state |
| North Carolina Medicaid · Nov 11, 2026 | No match | — |
| New York OMIG · Nov 11, 2026 | No match | — |
| Ohio Medicaid · Nov 11, 2026 | No match | — |
| Pennsylvania Medicheck · Nov 11, 2026 | No match | — |
| Washington HCA · Nov 11, 2026 | No match | — |
Official OIG search · How matching works ·Bulk check a roster
Medicare
| Enrollment (PECOS) | Not in the public enrollment file of Oct 1, 2026 |
|---|
Industry payments (Open Payments)
- 2025$158,025 · 7 payments from 3 companies
- 2024$28,520 · 5 payments from 3 companies
Top paying companies in 2025
| Company | Amount | Payments |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | $139,305 | 2 |
| Glaxosmithkline, LLC. | $17,640 | 4 |
| Acadia Pharmaceuticals Inc | $1,080 | 1 |
What the 2025 payments were for
- Consulting Fee$158,025 · 7 payments
Receiving payments does not imply wrongdoing. What Open Payments covers ·original records
Other cardiologists in San Francisco
- 1013198993
- 1013917046
- 1023192101
- 1063495166
- 1063705515
- 1093726879
- 1124062013
- 1134143506
- 1144586801
- 1184164030
- 1245318872
- 1245529940
All 159 cardiologists in San Francisco · All cardiologists in California